...
首页> 外文期刊>International journal of oncology >Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
【24h】

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

机译:马赛替尼拮抗ATP结合盒亚家族G成员2介导的多药耐药性

获取原文

摘要

In this in?vitro study, we determined whether masitinib could reverse multidrug resistance (MDR) in cells overexpressing the ATP binding cassette subfamily G member?2 (ABCG2) transporter. Masitinib (1.25 and 2.5?μM) significantly decreases the resistance to mitoxantrone (MX), SN38 and doxorubicin in HEK293 and H460 cells overexpressing the ABCG2 transporter. In addition, masitinib (2.5?μM) significantly increased the intracellular accumulation of [3H]-MX, a substrate for ABCG2, by inhibiting the function of ABCG2 and significantly decreased the efflux of [3H]-MX. However, masitinib (2.5?μM) did not significantly alter the expression of the ABCG2 protein. In addition, a docking model suggested that masitinib binds within the transmembrane region of a homology-modeled human ABCG2 transporter. Overall, our in?vitro findings suggest that masitinib reverses MDR to various anti-neoplastic drugs in HEK293 and H460 cells overexpressing ABCG2 by inhibiting their transport activity as opposed to altering their levels of expression.
机译:在这项体外研究中,我们确定了马赛替尼是否可以逆转过度表达ATP结合盒亚家族G成员2(ABCG2)转运蛋白的细胞中的多药耐药性(MDR)。马赛替尼(1.25和2.5?μM)明显降低了过表达ABCG2转运蛋白的HEK293和H460细胞对米托蒽醌(MX),SN38和阿霉素的抗性。此外,马赛替尼(2.5?μM)通过抑制ABCG2的功能显着增加了[3H] -MX(ABCG2的底物)的细胞内蓄积,并显着降低了[3H] -MX的流出。但是,马赛替尼(2.5?μM)并未显着改变ABCG2蛋白的表达。此外,对接模型表明,马赛替尼在同源模型人类ABCG2转运蛋白的跨膜区域内结合。总体而言,我们的体外研究结果表明,马赛替尼通过抑制其转运活性而不是改变其表达水平,将过表达ABCG2的HEK293和H460细胞中的MDR逆转为多种抗肿瘤药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号